For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Azilsartan medoxomil - Hypertension
PAD Profile : Azilsartan medoxomil - Hypertension
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Aliskiren
- Bendroflumethiazide
- Candesartan cilexetil
- Eprosartan
- Indapamide
- Irbesartan
- Losartan potassium
- Olmesartan medoxomil
- Valsartan
- Ramipril
- Amlodipine
- Lisinopril
- Bisoprolol fumarate
- Doxazosin mesilate
- Diltiazem hydrochloride
- Nifedipine
- Perindopril erbumine
- Telmisartan
- Moxonidine
- Co-tenidone (Atenolol/chlortalidone)
- Enalapril maleate
- Quinapril hydrochloride
- Nebivolol
- Perindopril arginine
- Metolazone
- Captopril
- Lercanidipine hydrochloride
- Nicardipine hydrochloride
- Chlortalidone
- Spironolactone
- Atenolol
- Carvedilol
- Celiprolol hydrochloride
- Metoprolol tartrate
- Propranolol hydrochloride
- Prazosin hydrochloride
- Clonidine hydrochloride
- Hydralazine hydrochloride
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the 1st line use of Angiotensin Receptor Blockers (ARBs) instead of an Angiotensin Converting Enzyme (ACE) inhibitor, for adults with hypertension where the use of an ARB or ACE is deemed equally appropriate.
Eprosartan and Azlisartan are not one of the locally preferred ARBs. See below
Losartan or candesartan - 1st line
Alternative options:
Irebsartan - Green
Telmisartan - Green
Valsartan - Green
Olmesartan - Green
Azlisartan - do not initiate in new patients
Eprosartan - do not initiate in new patients
Local hypertension guidelines / pathways will be reviewed and updated in light of this decision